EVALUATION OF THE IN VIVO BIODISTRIBUTION AND RADIATION DOSIMETRY OF 18F-AMBF3-TATE FOR USE AS A DIAGNOSTIC RADIOPHARMACEUTICAL
- Registry ID
- H19-03674
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- BC CANCER, PART OF THE PROVINCIAL HEALTH SERVICES AUTHORITY
- Start date
- 2020-03-09
- Last update
- 2020-01-31
Conditions
Related clinical trials
- A PHASE 2/3, MULTICENTER, RANDOMIZED OPEN LABEL STUDY OF ZANZALINTINIB VS EVEROLIMUS IN PARTICIPANTS WITH PREVIOUSLY TREATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NEUROENDOCRINE TUMOURS
- PHASE 1 FIRST-IN-HUMAN (FIH), DOSE ESCALATION AND DOSE EXPANSION STUDY OF RYZ401, A NOVEL RADIOPHARMACEUTICAL THERAPY LABELED WITH ACTINIUM-225 (225AC), IN SUBJECTS WITH NEUROENDOCRINE TUMORS (NETS) AND OTHER SELECTED SOLID TUMORS EXPRESSING SOMATOSTATIN RECEPTORS (SSTRS)
- LESION-TO-LESION COMPARISON OF 68GA-HADOTATATE, 18F-DOPA, AND 18F-FDG PET/CT IN THE EVALUATION OF METASTATIC NEUROENDOCRINE TUMORS
- A RANDOMIZED, MULTICENTER, OPEN-LABEL, ACTIVE-CONTROLLED PHASE 3 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF OCTREATIDE SUBCUTANEOUS DEPOT (CAM2029) VERSUS OCTREOTIDE LAR OR LANRETIDE ATG IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS
- A PHASE II STUDY OF [68]GA-HA-DOTATATE PET/CT IN THE EVALUATION OF LIVER METASTASIS IN ADULTS WITH NEUROENDOCRINE TUMORS
- EVALUATION OF THE SAFETY AND SENSITIVITY OF 68GA-DOTATOC PET/CT FOR IMAGING NET PATIENTS
View on source registry